- •PROGRESS IN BRAIN RESEARCH
- •List of Contributors
- •Preface
- •Epidemiology of primary glaucoma: prevalence, incidence, and blinding effects
- •Introduction
- •Prevalence of glaucoma
- •PAC suspect
- •PACG
- •Incidence of glaucoma
- •Blinding effects of glaucoma
- •Abbreviations
- •Acknowledgment
- •References
- •Predictive models to estimate the risk of glaucoma development and progression
- •Risk assessment in ocular hypertension and glaucoma
- •Risk factors for glaucoma development
- •Intraocular pressure
- •Corneal thickness
- •Cup/disc ratio and pattern standard deviation
- •The need for predictive models
- •Predictive models for glaucoma development
- •Predictive models for glaucoma progression
- •Limitations of predictive models
- •References
- •Intraocular pressure and central corneal thickness
- •Main text
- •References
- •Angle-closure: risk factors, diagnosis and treatment
- •Introduction
- •Mechanism
- •Other causes of angle closure
- •Risk factors
- •Age and gender
- •Ethnicity
- •Ocular biometry
- •Genetics
- •Diagnosis
- •Acute primary angle closure
- •Angle assessment in angle closure
- •Gonioscopy technique
- •Ultrasound biomicroscopy (UBM)
- •Scanning peripheral anterior chamber depth analyzer (SPAC)
- •Management
- •Acute primary angle closure
- •Medical therapy
- •Argon laser peripheral iridoplasty (ALPI)
- •Laser peripheral iridotomy (PI)
- •Lens extraction
- •Monitoring for subsequent IOP rise in eyes with APAC
- •Fellow eye of APAC
- •Chronic primary angle-closure glaucoma (CACG)
- •Laser peripheral iridotomy
- •Laser iridoplasty
- •Medical therapy
- •Trabeculectomy
- •Lens extraction
- •Combined lens extraction and trabeculectomy surgery
- •Goniosynechialysis
- •Summary
- •List of abbreviations
- •References
- •Early diagnosis in glaucoma
- •Introduction
- •History and examination
- •Quantitative tests and the diagnostic process
- •Pretest probability
- •Test validity
- •Diagnostic test performance
- •Posttest probability
- •Combing test results
- •Selective tests of visual function
- •Early glaucoma diagnosis from quantitative test results
- •Progression to make a diagnosis
- •Conclusions
- •Abbreviations
- •References
- •Monitoring glaucoma progression
- •Introduction
- •Monitoring structural damage progression
- •Monitoring functional damage progression
- •Abbreviations
- •References
- •Standard automated perimetry and algorithms for monitoring glaucoma progression
- •Standard automated perimetry
- •Global indices
- •HFA: MD, SF, PSD, CPSD
- •Octopus indices: MD, SF, CLV
- •OCTOPUS seven-in-one report (Fig. 2)
- •SAP VF assessment: full-threshold strategy
- •SAP VF defects assessment: OHTS criteria
- •SAP VF defects assessment: AGIS criteria
- •SAP VF defects assessment: CIGTS
- •Fastpac
- •Swedish interactive threshold algorithm
- •SAP VF assessment: the glaucoma staging system
- •SAP: interocular asymmetries in OHTS
- •SAP, VF progression
- •SAP: the relationship to other functional and structural diagnostic tests in glaucoma
- •SAP, FDP-Matrix
- •SAP, SWAP, HPRP, FDT
- •SAP: the relationship between function and structure
- •SAP, confocal scanning laser ophthalmoscopy, SLP-VCC
- •SAP, optical coherence tomography
- •SAP and functional magnetic resonance imaging
- •References
- •Introduction
- •Retinal ganglion cells: anatomy and function
- •Is glaucoma damage selective for any subgroup of RGCs?
- •Segregation
- •Isolation
- •FDT: rationale and perimetric techniques
- •SWAP: rationale and perimetric techniques
- •FDT: clinical data
- •SWAP: clinical data
- •Clinical data comparing FDT and SWAP
- •Conclusions
- •References
- •Scanning laser polarimetry and confocal scanning laser ophthalmoscopy: technical notes on their use in glaucoma
- •The GDx scanning laser polarimeter
- •Serial analysis
- •Limits
- •The Heidelberg retinal tomograph
- •Limits
- •Conclusions
- •References
- •The role of OCT in glaucoma management
- •Introduction
- •How OCT works
- •How OCT is performed
- •Evaluation of RNFL thickness
- •Evaluation of optic disc
- •OCT in glaucoma management
- •New perspective
- •Abbreviations
- •References
- •Introduction
- •Technology
- •Visual stimulation
- •Reproducibility and habituation of RFonh
- •Retinal neural activity as assessed from the electroretinogram (ERG)
- •The Parvo (P)- and Magno (M)-cellular pathways
- •Physiology
- •Magnitude and time course of RFonh in humans
- •Varying the parameters of the stimulus on RFonh
- •Luminance versus chromatic modulation
- •Frequency
- •Effect of pattern stimulation
- •Neurovascular coupling in humans
- •Clinical application
- •RFonh in OHT and glaucoma patients
- •Discussion
- •FLDF and neurovascular coupling in humans
- •Comments on clinical application of FLDF in glaucoma
- •Conclusions and futures directions
- •Acknowledgements
- •References
- •Advances in neuroimaging of the visual pathways and their use in glaucoma
- •Introduction
- •Conventional MR imaging and the visual pathways
- •Diffusion MR imaging
- •Functional MR imaging
- •Proton MR spectroscopy
- •References
- •Primary open angle glaucoma: an overview on medical therapy
- •Introduction
- •When to treat
- •Whom to treat
- •Genetics
- •Race
- •Ocular and systemic abnormalities
- •Tonometry and pachymetry
- •How to treat
- •Beta-blockers
- •Prostaglandins
- •Alpha-agonists
- •Carbonic anhydrase inhibitors (CAIs)
- •Myotics
- •Fixed combinations
- •References
- •The treatment of normal-tension glaucoma
- •Introduction
- •Epidemiology
- •Clinical features
- •Optic disk
- •Central corneal thickness
- •Disease course
- •Risk factors
- •Intraocular pressure
- •Local vascular factors
- •Immune mechanisms
- •Differential diagnosis
- •Diagnostic evaluation
- •Therapy
- •IOP reduction
- •Systemic medications
- •Neuroprotection
- •Noncompliance
- •Genetics of NTG
- •Abbreviations
- •References
- •The management of exfoliative glaucoma
- •Introduction
- •Epidemiology
- •Ocular and systemic associations
- •Ocular associations
- •Systemic associations
- •Pathogenesis of exfoliation syndrome
- •Mechanisms of glaucoma development
- •Management
- •Medical therapy
- •Laser surgery
- •Operative surgery
- •Future treatment of exfoliation syndrome and exfoliative glaucoma
- •Treatment directed at exfoliation material
- •References
- •Laser therapies for glaucoma: new frontiers
- •Background
- •Laser iridotomy
- •Indications
- •Contraindications
- •Patient preparation
- •Technique
- •Nd:YAG laser iridectomy
- •Argon laser iridectomy
- •Complications
- •LASER trabeculoplasty
- •Treatment technique
- •Mechanism of action
- •Indications for treatment
- •Contraindications to treatment
- •Patient preparation and postoperative follow-up
- •Complications of the treatment
- •Selective laser trabeculoplasty
- •Results
- •LASER iridoplasty
- •Indications
- •Contraindications
- •Treatment technique
- •Complications
- •LASER cyclophotocoagulation
- •Introduction
- •Indications and contraindications
- •Patient preparation
- •Transpupillary cyclophotocoagulation
- •Endoscopic cyclophotocoagulation
- •Transscleral cyclophotocoagulation
- •Transscleral noncontact cyclophotocoagulation
- •Transscleral contact cyclophotocoagulation
- •Complications
- •Excimer laser trabeculotomy
- •References
- •Modulation of wound healing during and after glaucoma surgery
- •The process of wound healing
- •Using surgical and anatomical principles to modify therapy
- •Growth factors
- •Cellular proliferation and vascularization
- •Cell motility, matrix contraction and synthesis
- •Drug delivery
- •Future directions: total scarring control and tissue regeneration
- •Acknowledgments
- •References
- •Surgical alternative to trabeculectomy
- •Introduction
- •Deep sclerectomy
- •Viscocanalostomy
- •Conclusions
- •References
- •Modern aqueous shunt implantation: future challenges
- •Background
- •Current shunts and factors affecting their function
- •Shunt-related factors
- •Surface area
- •Plate material
- •Valved versus non-valved
- •Commercially available devices
- •Comparative studies
- •Patient and ocular factors
- •Severity of glaucoma damage
- •Tolerance of topical ocular hypotensive medications
- •Aqueous hyposecretion
- •Previous ocular surgery
- •Scleral thinning
- •Patient cooperation for and tolerance of potential slit-lamp interventions
- •Future challenges
- •Predictability
- •Cataract formation
- •The long-term effect on the cornea
- •References
- •Model systems for experimental studies: retinal ganglion cells in culture
- •Mixed RGCs in culture
- •Retinal explants
- •Glial cultures
- •RGC-5 cells
- •Differentiation of RGC-5 cells
- •RGC-5 cell neurites
- •Advantages and disadvantages of culture models
- •References
- •Rat models for glaucoma research
- •Rat models for glaucoma research
- •Use of animal models for POAG
- •Suitability of the rat for models of optic nerve damage in POAG
- •Methods for measuring IOP in rats
- •General considerations for measuring IOP in rats
- •Assessing optic nerve and retina damage
- •Experimental methods of producing elevated IOP
- •Laser treatment of limbal tissues
- •Episcleral vein cautery
- •Conclusions
- •Abbreviations
- •Acknowledgements
- •References
- •Mouse genetic models: an ideal system for understanding glaucomatous neurodegeneration and neuroprotection
- •Introduction
- •The mouse as a model system
- •Mice are suitable models for studying IOP elevation in glaucoma
- •Tools for glaucoma research
- •Accurate IOP measurements are fundamental to the study of glaucoma
- •The future of IOP assessment
- •Assessment of RGC function
- •Mouse models of glaucoma
- •Primary open-angle glaucoma
- •MYOC
- •OPTN
- •Strategies for developing new models of POAG
- •Developmental glaucoma
- •Pigmentary glaucoma
- •Experimentally induced models of glaucoma
- •Mouse models to characterize processes involved in glaucomatous neurodegeneration
- •Similar patterns of glaucomatous damage occur in humans and mice
- •The lamina cribrosa is an important site of early glaucomatous damage
- •An insult occurs to the axons of RGCs within the lamina in glaucoma
- •What is the nature of the insult at the lamina?
- •Other changes occur in the retina in glaucoma
- •PERG and complement
- •Using mouse models to develop neuroprotective strategies
- •Somal protection
- •Axonal protection
- •Erythropoietin administration
- •Radiation-based treatment
- •References
- •Clinical trials in neuroprotection
- •Introduction
- •Methods of clinical studies
- •Issues in the design and conduct of clinical trials
- •Clinical trials of neuroprotection
- •Clinical trials of neuroprotection in ophthalmology
- •Endpoints
- •Neuroprotection and glaucoma
- •Conclusions
- •Abbreviations
- •References
- •Pathogenesis of ganglion ‘‘cell death’’ in glaucoma and neuroprotection: focus on ganglion cell axonal mitochondria
- •Introduction
- •Retinal ganglion cells and mitochondria
- •Possible causes for ganglion cell death in glaucoma
- •Mitochondrial functions and apoptosis
- •Mitochondrial function enhancement and the attenuation of ganglion cell death
- •Creatine
- •Nicotinamide
- •Epigallocatechin gallate
- •Conclusion
- •References
- •Astrocytes in glaucomatous optic neuropathy
- •Introduction
- •Quiescent astrocytes
- •Reactive astrocytes in glaucoma
- •Signal transduction in glaucomatous astrocytes
- •Protein tyrosine kinases (PTKs)
- •Serine/threonine protein mitogen-activated kinases (MAPKs)
- •G protein-coupled receptors
- •Ras superfamily of small G proteins
- •Astrocyte migration in the glaucomatous optic nerve head
- •Cell adhesion of ONH astrocytes
- •Connective tissue changes in the glaucomatous optic nerve head
- •Extracellular matrix synthesis by ONH astrocytes
- •Extracellular matrix degradation by reactive astrocytes
- •Oxidative stress in ONH astrocytes
- •Conclusions
- •Acknowledgments
- •References
- •Glaucoma as a neuropathy amenable to neuroprotection and immune manipulation
- •Glaucoma as a neurodegenerative disease
- •Oxidative stress and free radicals
- •Excessive glutamate, increased calcium levels, and excitotoxicity
- •Deprivation of neurotrophins and growth factors
- •Abnormal accumulation of proteins
- •Pharmacological neuroprotection for glaucoma
- •Protection of the retinal ganglion cells involves the immune system
- •Searching for an antigen for potential glaucoma therapy
- •Concluding remarks
- •References
- •Oxidative stress and glaucoma: injury in the anterior segment of the eye
- •Introduction
- •Oxidative stress
- •Trabecular meshwork
- •IOP increase and free radicals
- •Glaucomatous cascade
- •Nitric oxide and endothelins
- •Extracellular matrix
- •Metalloproteinases
- •Other factors of interest
- •Therapeutic and preventive substances of interest in glaucoma
- •Ginkgo biloba extract
- •Green tea
- •Ginseng
- •Memantine and its derivates
- •Conclusions
- •Abbreviations
- •References
- •Conclusions on neuroprotective treatment targets in glaucoma
- •Acknowledgments
- •References
- •Involvement of the Bcl2 gene family in the signaling and control of retinal ganglion cell death
- •Introduction
- •Intrinsic apoptosis vs. extrinsic apoptosis
- •The Bcl2 family of proteins
- •The requirement of BAX for RGC soma death
- •BH3-only proteins and the early signaling of ganglion cell apoptosis
- •Conclusion
- •Abbreviations
- •Acknowledgments
- •References
- •Assessment of neuroprotection in the retina with DARC
- •Introduction
- •DARC
- •Introducing the DARC technique
- •Annexin 5-labeled apoptosis and ophthalmoloscopy
- •Detection of RGC apoptosis in glaucoma-related animal models with DARC
- •Assessment of glutamate modulation with DARC
- •Glutamate at synaptic endings
- •Glutamate excitotoxicity in glaucoma
- •Assessment of coenzyme Q10 in glaucoma-related models with DARC
- •Summary
- •Abbreviations
- •Acknowledgment
- •References
- •Potential roles of (endo)cannabinoids in the treatment of glaucoma: from intraocular pressure control to neuroprotection
- •Introduction
- •The endocannabinoid system in the eye
- •The IOP-lowering effects of endocannabinoids
- •Endocannabinoids and neuroprotection
- •Conclusions
- •References
- •Glaucoma of the brain: a disease model for the study of transsynaptic neural degeneration
- •Retinal ganglion cells, retino-geniculate neurons
- •Lateral geniculate nucleus
- •Mechanisms of RGC injury in glaucoma
- •Transsynaptic degeneration of the lateral geniculate nucleus in glaucoma
- •Neural degeneration in magno-, parvo-, and koniocellular LGN layers
- •Visual cortex in glaucoma
- •Neuropathology of glaucoma in the visual pathways in the human brain
- •Mechanisms of glaucoma damage in the central visual pathways
- •Implications of central visual system injury in glaucoma
- •Conclusion
- •Acknowledgments
- •References
- •Clinical relevance of optic neuropathy
- •Is there a remodeling of retinal circuitry?
- •Behavioral consequences of glaucoma
- •Glaucoma as a neurodegenerative disease versus neuroplasticity and adaptive changes
- •Future directions
- •Acknowledgment
- •References
- •Targeting excitotoxic/free radical signaling pathways for therapeutic intervention in glaucoma
- •Introduction
- •Channel properties of NMDA receptors correlated with excitotoxicity
- •Downstream signaling cascades after overactivation of NMDA receptors
- •Relevance of excitotoxicity to glaucoma
- •Therapeutic approaches to prevent RGC death by targeting the pathways involved in NMDA excitotoxicity
- •Drugs targeting NMDA receptors
- •Kinetics of NMDA receptor antagonists
- •Memantine
- •NitroMemantines
- •Drugs targeting downstream signaling molecules in NMDA-induced cell death pathways
- •p38 MAPK inhibitors
- •Averting caspase-mediated neurodegeneration
- •Abbreviations
- •Acknowledgments
- •References
- •Stem cells for neuroprotection in glaucoma
- •Introduction
- •Glaucoma as a model of neurodegenerative disease
- •Why use stem cells for neuroprotective therapy?
- •Stem cell sources
- •Neuroprotection by transplanted stem cells
- •Endogenous stem cells
- •Key challenges
- •Conclusion
- •Abbreviations
- •Acknowledgments
- •References
- •The relationship between neurotrophic factors and CaMKII in the death and survival of retinal ganglion cells
- •Introduction
- •Glaucoma and the RGCs
- •Are other retinal cells affected in glaucoma?
- •Retinal ischemia related glaucoma
- •Excitotoxicity and the retina
- •Signal transduction
- •NMDA receptor antagonists and CaMKII
- •Caspase-3 activation in NMDA-induced retinal cell death and its inhibition by m-AIP
- •BDNF and neuroprotection of RGCs
- •Summary and conclusions
- •Abbreviations
- •Acknowledgments
- •References
- •Evidence of the neuroprotective role of citicoline in glaucoma patients
- •Introduction
- •Patients: selection and recruitment criteria
- •Pharmacological treatment protocol
- •Methodology of visual function evaluation: electrophysiological examinations
- •PERG recordings
- •VEP recordings
- •Statistic evaluation of electrophysiological results
- •Electrophysiological (PERG and VEP) responses in OAG patients after the second period of evaluation
- •Effects of citicoline on retinal function in glaucoma patients: neurophysiological implications
- •Effects of citicoline on neural conduction along the visual pathways in glaucoma patients: neurophysiological implications
- •Possibility of neuroprotective role of citicoline in glaucoma patients
- •Conclusive remarks
- •Abbreviations
- •References
- •Neuroprotection: VEGF, IL-6, and clusterin: the dark side of the moon
- •Neuroprotection: VEGF-A, a shared growth factor
- •VEGF-A isoforms
- •VEGF-A receptors
- •Angiogenesis, mitogenesis, and endothelial survival
- •Neurotrophic and neuroprotective effect
- •Intravitreal VEGF inhibition therapy and neuroretina toxicity
- •Neuroprotection: clusterin, a multifunctional protein
- •Clusterin/ApoJ: a debated physiological role
- •Clusterin and diseases
- •Clusterin and the nervous system
- •Neuroprotection: IL-6, VEGF, clusterin, and glaucoma
- •Rational basis for the development of coenzyme Q10 as a neurotherapeutic agent for retinal protection
- •Introduction
- •Ischemia model
- •Neuroprotective effect of Coenzyme Q10 against cell loss yielded by transient ischemia in the RGC layer
- •Retinal ischemia and glutamate
- •Coenzyme Q10 minimizes glutamate increase induced by ischemia/reperfusion
- •Summary
- •Acknowledgment
- •References
- •17beta-Estradiol prevents retinal ganglion cell loss induced by acute rise of intraocular pressure in rat
- •Methods
- •Morphometric analysis
- •Microdialysis
- •Drug application
- •Statistical analysis
- •Results
- •17beta-Estradiol pretreatment minimizes RGC loss
- •Discussion
- •Acknowledgment
Abbreviations |
|
AIF |
apoptosis-inducing factor |
CaM |
calmodulin |
EAAT |
excitatory amino acid transporter |
HIV |
human immunodeficiency virus |
IOP |
intraocular pressure |
MAPK |
mitogen-activated protein kinase |
MEF2C |
myocyte enhancer factor 2C |
NMDA |
N-methyl-D-aspartate |
NMDAR |
NMDA receptor |
nNOS |
neuronal nitric oxide synthase |
NO |
nitric oxide |
PARP |
poly(ADP-ribose) polymerase |
PSD-95 |
postsynaptic density-95 |
RGC |
retinal ganglion cell |
ROS |
reactive oxygen species |
Acknowledgments
We thank our collaborators and colleagues, present and former, for their contributions to this work. We are especially grateful to J. Bormann, Y.-B. Choi, H.-S. V. Chen, M. Kikuchi, S. Manabe, C. M. Troy, and M. L. Shelanski. This work was supported in part by National Institutes of Health grants R01 EY05477 and R01 EY09024 (to S.A.L), Allergan, Inc. (to S.A.L.), Astellas Foundation for Research on Metabolic Disorders (to M.S.), and the Japanese Society for the Promotion of Science (JSPS Postdoctoral Fellowship for Research Abroad to M.S).
References
Aizenman, E., Frosch, M.P. and Lipton, S.A. (1988) Responses mediated by excitatory amino acid receptors in solitary retinal ganglion cells from rat. J. Physiol., 396: 75–91.
Ambati, J., Chalam, K.V., Chawla, D.K., D’Angio, C.T., Guillet, E.G., Rose, S.J., Vanderlinde, R.E. and Ambati, B.K. (1997) Elevated gamma-aminobutyric acid, glutamate, and vascular endothelial growth factor levels in the vitreous of patients with proliferative diabetic retinopathy. Arch. Ophthalmol., 115(9): 1161–1166.
Ankarcrona, M., Dypbukt, J.M., Bonfoco, E., Zhivotovsky, B., Orrenius, S., Lipton, S.A. and Nicotera, P. (1995) Glutamateinduced neuronal death: a succession of necrosis or apoptosis depending on mitochondrial function. Neuron, 15(4): 961–973.
507
Arundine, M., Chopra, G.K., Wrong, A., Lei, S., Aarts, M.M., MacDonald, J.F. and Tymianski, M. (2003) Enhanced vulnerability to NMDA toxicity in sublethal traumatic neuronal injury in vitro. J. Neurotrauma, 20(12): 1377–1395.
Billups, B. and Attwell, D. (1996) Modulation of non-vesicular glutamate release by pH. Nature, 379(6561): 171–174.
Bonfoco, E., Krainc, D., Ankarcrona, M., Nicotera, P. and Lipton, S.A. (1995) Apoptosis and necrosis: two distinct events induced, respectively, by mild and intense insults with N-methyl-D-aspartate or nitric oxide/superoxide in cortical cell cultures. Proc. Natl. Acad. Sci. U.S.A., 92(16): 7162–7166.
Bossy-Wetzel, E., Talantova, M.V., Lee, W.D., Scholzke, M.N., Harrop, A., Mathews, E., Gotz, T., Han, J., Ellisman, M.H., Perkins, G.A. and Lipton, S.A. (2004) Crosstalk between nitric oxide and zinc pathways to neuronal cell death involving mitochondrial dysfunction and p38-activated K+ channels. Neuron, 41(3): 351–365.
Brandstatter, J.H., Hartveit, E., Sassoe-Pognetto, M. and Wassle, H. (1994) Expression of NMDA and high-affinity kainate receptor subunit mRNAs in the adult rat retina. Eur. J. Neurosci., 6(7): 1100–1112.
Burgoyne, C.F., Downs, J.C., Bellezza, A.J., Suh, J.K. and Hart, R.T. (2005) The optic nerve head as a biomechanical structure: a new paradigm for understanding the role of IOPrelated stress and strain in the pathophysiology of glaucomatous optic nerve head damage. Prog. Retin. Eye Res., 24(1): 39–73.
Cao, J., Viholainen, J.I., Dart, C., Warwick, H.K., Leyland, M.L. and Courtney, M.J. (2005) The PSD95-nNOS interface: a target for inhibition of excitotoxic p38 stress-activated protein kinase activation and cell death. J. Cell Biol., 168(1): 117–126.
Chen, H.-S.V. and Lipton, S.A. (1997) Mechanism of memantine block of NMDA-activated channels in rat retinal ganglion cells: uncompetitive antagonism. J. Physiol., 499(Pt 1): 27–46.
Chen, H.-S.V. and Lipton, S.A. (2006) The chemical biology of clinically tolerated NMDA receptor antagonists. J. Neurochem., 97(6): 1611–1626.
Chen, H.-S.V., Pellegrini, J.W., Aggarwal, S.K., Lei, S.Z., Warach, S., Jensen, F.E. and Lipton, S.A. (1992) Openchannel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptormediated neurotoxicity. J. Neurosci., 12(11): 4427–4436.
Chen, H.-S.V., Wang, Y.F., Rayudu, P.V., Edgecomb, P., Neill, J.C., Segal, M.M., Lipton, S.A. and Jensen, F.E. (1998) Neuroprotective concentrations of the N-methyl-D-aspartate open-channel blocker memantine are effective without cytoplasmic vacuolation following post-ischemic administration and do not block maze learning or long-term potentiation. Neuroscience, 86(4): 1121–1132.
Choi, D.W. (1988) Glutamate neurotoxicity and diseases of the nervous system. Neuron, 1(8): 623–634.
Choi, Y.-B., Tenneti, L., Le, D.A., Ortiz, J., Bai, G., Chen, H.-S.V. and Lipton, S.A. (2000) Molecular basis of NMDA receptorcoupled ion channel modulation by S-nitrosylation. Nat. Neurosci., 3(1): 15–21.
508
Christopherson, K.S., Hillier, B.J., Lim, W.A. and Bredt, D.S. (1999) PSD-95 assembles a ternary complex with the N-methyl-D-aspartic acid receptor and a bivalent neuronal NO synthase PDZ domain. J. Biol. Chem., 274(39): 27467–27473.
Dawson, V.L. and Dawson, T.M. (1996) Nitric oxide neurotoxicity. J. Chem. Neuroanat., 10(3–4): 179–190.
Dawson, V.L., Dawson, T.M., Bartley, D.A., Uhl, G.R. and Snyder, S.H. (1993) Mechanisms of nitric oxide-mediated neurotoxicity in primary brain cultures. J. Neurosci., 13(6): 2651–2661.
Dawson, V.L., Dawson, T.M., London, E.D., Bredt, D.S. and Snyder, S.H. (1991) Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures. Proc. Natl. Acad. Sci. U.S.A., 88(14): 6368–6371.
Domino, E.F. and Luby, E.D. (1981) Abnormal mental states induced by phencyclidine as a model of schizophrenia. In: Domino E.F. (Ed.), PCP (Phenyclidine): Historical and Current Perspectives. NPP Books, Ann Arbor, pp. 401–418.
Dreyer, E.B. and Lipton, S.A. (1999) New perspectives on glaucoma. JAMA, 281(4): 306–308.
Dreyer, E.B., Zurakowski, D., Schumer, R.A., Podos, S.M. and Lipton, S.A. (1996) Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma. Arch. Ophthalmol., 114(3): 299–305.
El-Remessy, A.B., Khalil, I.E., Matragoon, S., Abou-Mohamed, G., Tsai, N.-J., Roon, P., Caldwell, R.B., Caldwell, R.W., Green, K. and Liou, G.I. (2003) Neuroprotective effect of (-){Delta}9-tetrahydrocannabinol and cannabidiol in N- methyl–aspartate-induced retinal neurotoxicity: involvement of peroxynitrite. Am. J. Pathol., 163(5): 1997–2008.
Flammer, J. and Orgul, S. (1998) Optic nerve blood-flow abnormalities in glaucoma. Prog. Retin. Eye Res., 17(2): 267–289.
Furukawa, Y., Okada, M., Akaike, N., Hayashi, T. and Nabekura, J. (2000) Reduction of voltage-dependent magnesium block of N-methyl-D-aspartate receptor-mediated current by in vivo axonal injury. Neuroscience, 96(2): 385–392.
Goebel, D.J. and Winkler, B.S. (2006) Blockade of PARP activity attenuates poly(ADP-ribosyl)ation but offers only partial neuroprotection against NMDA-induced cell death in the rat retina. J. Neurochem., 98(6): 1732–1745.
Green, D.R. and Reed, J.C. (1998) Mitochondria and apoptosis. Science, 281(5381): 1309–1312.
Grunder, T., Kohler, K., Kaletta, A. and Guenther, E. (2000) The distribution and developmental regulation of NMDA receptor subunit proteins in the outer and inner retina of the rat. J. Neurobiol., 44(3): 333–342.
Guo, H. and Huang, L.Y.M. (2001) Alteration in the voltage dependence of NMDA receptor channels in rat dorsal horn neurones following peripheral inflammation. J. Physiol., 537(1): 115–123.
Hahn, J.S., Aizenman, E. and Lipton, S.A. (1988) Central mammalian neurons normally resistant to glutamate toxicity are made sensitive by elevated extracellular Ca2+: toxicity is blocked by the N-methyl-D-aspartate antagonist MK-801. Proc. Natl. Acad. Sci. U.S.A., 85(17): 6556–6560.
Harada, T., Harada, C., Nakamura, K., Quah, H.M., Okumura, A., Namekata, K., Saeki, T., Aihara, M., Yoshida, H., Mitani, A. and Tanaka, K. (2007) The potential role of glutamate transporters in the pathogenesis of normal tension glaucoma. J. Clin. Invest., 117(7): 1763–1770.
Hardingham, G.E. and Bading, H. (2003) The Yin and Yang of NMDA receptor signalling. Trends Neurosci., 26(2): 81–89.
Hare, W.A., WoldeMu¨ssie, E., Lai, R.K., Ton, H., Ruiz, G., Chun, T. and Wheeler, L. (2004a) Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, I: Functional measures. Invest. Ophthalmol. Vis. Sci., 45(8): 2625–2639.
Hare, W., WoldeMu¨ssie, E., Lai, R., Ton, H., Ruiz, G., Feldmann, B., Wijono, M., Chun, T. and Wheeler, L. (2001) Efficacy and safety of memantine, an NMDA-type openchannel blocker, for reduction of retinal injury associated with experimental glaucoma in rat and monkey. Surv. Ophthalmol., 45(Suppl 3): S284–S289.
Hare, W.A., WoldeMu¨ssie, E., Weinreb, R.N., Ton, H., Ruiz, G., Wijono, M., Feldmann, B., Zangwill, L. and Wheeler, L. (2004b) Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, II: Structural measures. Invest. Ophthalmol. Vis. Sci., 45(8): 2640–2651.
Hartveit, E., Brandstatter, J.H., Sassoe-Pognetto, M., Laurie, D.J., Seeburg, P.H. and Wassle, H. (1994) Localization and developmental expression of the NMDA receptor subunit NR2A in the mammalian retina. J. Comp. Neurol., 348(4): 570–582.
Hess, D.T., Matsumoto, A., Kim, S.O., Marshall, H.E. and Stamler, J.S. (2005) Protein S-nitrosylation: purview and parameters. Nat. Rev. Mol. Cell. Biol., 6(2): 150–166.
Honkanen, R.A., Baruah, S., Zimmerman, M.B., Khanna, C.L., Weaver, Y.K., Narkiewicz, J., Waziri, R., Gehrs, K.M., Weingeist, T.A., Boldt, H.C., Folk, J.C., Russell, S.R. and Kwon, Y.H. (2003) Vitreous amino acid concentrations in patients with glaucoma undergoing vitrectomy. Arch. Ophthalmol., 121(2): 183–188.
Javitt, D.C. and Zukin, S.R. (1991) Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry, 148(10): 1301–1308.
Kawasaki, H., Morooka, T., Shimohama, S., Kimura, J., Hirano, T., Gotoh, Y. and Nishida, E. (1997) Activation and involvement of p38 mitogen-activated protein kinase in glutamate-induced apoptosis in rat cerebellar granule cells. J. Biol. Chem., 272(30): 18518–18521.
Kikuchi, M., Tenneti, L. and Lipton, S.A. (2000) Role of p38 mitogen-activated protein kinase in axotomy-induced apoptosis of rat retinal ganglion cells. J. Neurosci., 20(13): 5037–5044.
Klein, B.E., Klein, R., Sponsel, W.E., Franke, T., Cantor, L.B., Martone, J. and Menage, M.J. (1992) Prevalence of glaucoma. The beaver dam eye study. Ophthalmology, 99(10): 1499–1504.
Kornau, H.C., Schenker, L.T., Kennedy, M.B. and Seeburg, P.H. (1995) Domain interaction between NMDA receptor
subunits and the postsynaptic density protein PSD-95. Science, 269(5231): 1737–1740.
Lafon-Cazal, M., Pietri, S., Culcasi, M. and Bockaert, J. (1993) NMDA-dependent superoxide production and neurotoxicity. Nature, 364(6437): 535–537.
Lee, J.C., Laydon, J.T., McDonnell, P.C., Gallagher, T.F., Kumar, S., Green, D., McNulty, D., Blumenthal, M.J., Keys, J.R., Landvatter, S.W., Strickler, J.E., McLaughlin, M.M., Siemens, I.R., Fisher, S.M., Livi, G.P., White, J.R., Adams, J.L. and Young, P.R. (1994) A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature, 372(6508): 739–746.
Leppik, I.E. (1988) MK-801 for epilepsy: a pilot study. Neurology, 38(Suppl. 1): p. 405.
Li, S., Mealing, G.A.R., Morley, P. and Stys, P.K. (1999) Novel injury mechanism in anoxia and trauma of spinal cord white matter: glutamate release via reverse Na+-dependent glutamate transport. J. Neurosci., 19(14): 16RC–16RC.
Lipton, S.A. (1993) Prospects for clinically tolerated NMDA antagonists: open-channel blockers and alternative redox states of nitric oxide. Trends Neurosci., 16(12): 527–532.
Lipton, S.A. (1999) Neuronal protection and destruction by NO. Cell Death Differ., 6(10): 943–951.
Lipton, S.A. (2001) Retinal ganglion cells, glaucoma and neuroprotection. Prog. Brain Res., 131: 712–718.
Lipton, S.A. (2003) Possible role for memantine in protecting retinal ganglion cells from glaucomatous damage. Surv. Ophthalmol., 48(Suppl 1): S38–S46.
Lipton, S.A. (2004) Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults. NeuroRx, 1(1): 101–110.
Lipton, S.A. (2006) Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat. Rev. Drug Discov., 5(2): 160–170.
Lipton, S.A. (2007) Pathologically activated therapeutics for neuroprotection. Nat. Rev. Neurosci., 8(10): 803–808.
Lipton, S.A., Choi, Y.B., Pan, Z.H., Lei, S.Z., Chen, H.-S.V., Sucher, N.J., Loscalzo, J., Singel, D.J. and Stamler, J.S. (1993) A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitrosocompounds. Nature, 364(6438): 626–632.
Lipton, S.A., Rayudu, P.V., Choi, Y.B., Sucher, N.J. and Chen, H.-S.V. (1998) Redox modulation of the NMDA receptor by NO-related species. Prog. Brain Res., 118: 73–82.
Lipton, S.A. and Rosenberg, P.A. (1994) Excitatory amino acids as a final common pathway for neurologic disorders. N. Engl. J. Med., 330(9): 613–622.
Lucas, D.R. and Newhouse, J.P. (1957) The toxic effect of sodium L-glutamate on the inner layers of the retina. AMA Arch. Ophthalmol., 58(2): 193–201.
Manabe, S. and Lipton, S. (2003) Divergent NMDA signals leading to proapoptotic and antiapoptotic pathways in the rat retina. Invest. Ophthalmol. Vis. Sci., 44(1): 385–392.
Mao, Z., Bonni, A., Xia, F., Nadal-Vicens, M. and Greenberg, M.E. (1999) Neuronal activity-dependent cell survival mediated by transcription factor MEF2. Science, 286(5440): 785–790.
509
Mayer, M.L., Westbrook, G.L. and Guthrie, P.B. (1984) Voltage-dependent block by Mg2+ of NMDA responses in spinal cord neurones. Nature, 309(5965): 261–263.
Muir, K.W. and Lees, K.R. (1995) Clinical experience with excitatory amino acid antagonist drugs. Stroke, 26(3): 503–513.
Nakamura, T. and Lipton, S.A. (2007) S-Nitrosylation and uncompetitive/fast off-rate (UFO) drug therapy in neurodegenerative disorders of protein misfolding. Cell Death Differ., 14(7): 1305–1314.
Naskar, R., Vorwerk, C.K. and Dreyer, E.B. (2000) Concurrent downregulation of a glutamate transporter and receptor in glaucoma. Invest. Ophthalmol. Vis. Sci., 41(7): 1940–1944.
Nowak, L., Bregestovski, P., Ascher, P., Herbet, A. and Prochiantz, A. (1984) Magnesium gates glutamate-activated channels in mouse central neurones. Nature, 307(5950): 462–465.
Okamoto, S., Krainc, D., Sherman, K. and Lipton, S.A. (2000) Antiapoptotic role of the p38 mitogen-activated protein kinase-myocyte enhancer factor 2 transcription factor pathway during neuronal differentiation. Proc. Natl. Acad. Sci. U.S.A., 97(13): 7561–7566.
Olney, J.W. and Ho, O.L. (1970) Brain damage in infant mice following oral intake of glutamate, aspartate or cysteine. Nature, 227(5258): 609–611.
Orgogozo, J.M., Rigaud, A.S., Stoffler, A., Mobius, H.J. and Forette, F. (2002) Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke, 33(7): 1834–1839.
Osborne, N.N. (1999) Memantine reduces alterations to the mammalian retina, in situ, induced by ischemia. Vis. Neurosci., 16(1): 45–52.
Osborne, N.N., Melena, J., Chidlow, G. and Wood, J.P.M. (2001) A hypothesis to explain ganglion cell death caused by vascular insults at the optic nerve head: possible implication for the treatment of glaucoma. Br. J. Ophthalmol., 85(10): 1252–1259.
Ott, B.R., Blake, L.M., Kagan, E. and Resnick, M. (2007) Open label, multicenter, 28 week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer’s disease. J. Neurol., 254(3): 351–358.
Quigley, H.A. (1995) Ganglion cell death in glaucoma: pathology recapitulates ontogeny. Aust. N. Z. J. Ophthalmol., 23(2): 85–91.
Quigley, H.A. (1999) Neuronal death in glaucoma. Prog. Retin. Eye Res., 18(1): 39–57.
Reisberg, B., Doody, R., Stoffler, A., Schmitt, F., Ferris, S. and Mobius, H.J. (2003) Memantine in moderate-to-severe Alzheimer’s disease. N. Engl. J. Med., 348(14): 1333–1341.
Reisberg, B., Doody, R., Stoffler, A., Schmitt, F., Ferris, S. and Mobius, H.J. (2006) A 24 week open-label extension study of memantine in moderate to severe Alzheimer disease. Arch. Neurol., 63(1): 49–54.
Sattler, R., Xiong, Z., Lu, W.Y., Hafner, M., MacDonald, J.F. and Tymianski, M. (1999) Specific coupling of NMDA
510
receptor activation to nitric oxide neurotoxicity by PSD-95 protein. Science, 284(5421): 1845–1848.
Schifitto, G., Navia, B.A., Yiannoutsos, C.T., Marra, C.M., Chang, L., Ernst, T., Jarvik, J.G., Miller, E.N., Singer, E.J., Ellis, R.J., Kolson, D.L., Simpson, D., Nath, A., Berger, J., Shriver, S.L., Millar, L.L., Colquhoun, D., Lenkinski, R., Gonzalez, R.G. and Lipton, S.A. (2007) Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study. AIDS, 21(14): 1877–1886.
Semenova, M.M., Maki-Hokkonen, A.M.J., Cao, J., Komarovski, V., Forsberg, K.M., Koistinaho, M., Coffey, E.T. and Courtney, M.J. (2007) Rho mediates calcium-dependent activation of p38alpha and subsequent excitotoxic cell death. Nat. Neurosci., 10(4): 436–443.
Shiose, Y., Kitazawa, Y., Tsukahara, S., Akamatsu, T., Mizokami, K., Futa, R., Katsushima, H. and Kosaki, H. (1991) Epidemiology of glaucoma in Japan — a nationwide glaucoma survey. Jpn. J. Ophthalmol., 35(2): 133–155.
Sucher, N.J., Aizenman, E. and Lipton, S.A. (1991) N-Methyl- D-aspartate antagonists prevent kainate neurotoxicity in rat retinal ganglion cells in vitro. J. Neurosci., 11(4): 966–971.
Sullivan, J.M., Traynelis, S.F., Chen, H.-S.V., Escobar, W., Heinemann, S.F. and Lipton, S.A. (1994) Identification of two cysteine residues that are required for redox modulation of the NMDA subtype of glutamate receptor. Neuron, 13(4): 929–936.
Szatkowski, M. and Attwell, D. (1994) Triggering and execution of neuronal death in brain ischaemia: two phases of glutamate release by different mechanisms. Trends Neurosci., 17(9): 359–365.
Tenneti, L., D’Emilia, D.M., Troy, C.M. and Lipton, S.A. (1998) Role of caspases in N-methyl-D-aspartate-induced apoptosis in cerebrocortical neurons. J. Neurochem., 71(3): 946–959.
Tezel, G. and Wax, M.B. (2004) The immune system and glaucoma. Curr. Opin. Ophthalmol., 15(2): 80–84.
Troy, C.M., Stefanis, L., Prochiantz, A., Greene, L.A. and Shelanski, M.L. (1996) The contrasting roles of ICE family proteases and interleukin-1beta in apoptosis induced by trophic factor withdrawal and by copper/zinc superoxide dismutase down-regulation. Proc Natl. Acad. Sci. U.S.A., 93(11): 5635–5640.
Vorwerk, C.K., Lipton, S.A., Zurakowski, D., Hyman, B.T., Sabel, B.A. and Dreyer, E.B. (1996) Chronic low-dose glutamate is toxic to retinal ganglion cells. Toxicity blocked by memantine. Invest. Ophthalmol. Vis. Sci., 37(8): 1618–1624.
Wakabayashi, Y., Yagihashi, T., Kezuka, J., Muramatsu, D., Usui, M. and Iwasaki, T. (2006) Glutamate levels in aqueous humor of patients with retinal artery occlusion. Retina, 26(4): 432–436.
Wilcock, G., Mobius, H.J. and Stoffler, A. (2002) A doubleblind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int. Clin. Psychopharmacol., 17(6): 297–305.
Wilson, K.P., McCaffrey, P.G., Hsiao, K., Pazhanisamy, S., Galullo, V., Bemis, G.W., Fitzgibbon, M.J., Caron, P.R., Murcko, M.A. and Su, M.S.S. (1997) The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase. Chem. Biol., 4(6): 423–431.
WoldeMu¨ssie, E., Yoles, E., Schwartz, M., Ruiz, G. and Wheeler, L.A. (2002) Neuroprotective effect of memantine in different retinal injury models in rats. J. Glaucoma, 11(6): 474–480.
Xia, Z., Dickens, M., Raingeaud, J., Davis, R.J. and Greenberg, M.E. (1995) Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science, 270(5240): 1326–1331.
Yu, S.W., Andrabi, S.A., Wang, H., Kim, N.S., Poirier, G.G., Dawson, T.M. and Dawson, V.L. (2006) Apoptosis-inducing factor mediates poly(ADP-ribose) (PAR) polymer-induced cell death. Proc. Natl. Acad. Sci. U.S.A., 103(48): 18314–18319.
Yu, S.W., Wang, H., Dawson, T.M. and Dawson, V.L. (2003) Poly(ADP-ribose) polymerase-1 and apoptosis inducing factor in neurotoxicity. Neurobiol. Dis., 14(3): 303–317.
Yucel, Y.H., Gupta, N., Zhang, Q., Mizisin, A.P., Kalichman, M.W. and Weinreb, R.N. (2006) Memantine protects neurons from shrinkage in the lateral geniculate nucleus in experimental glaucoma. Arch. Ophthalmol., 124(2): 217–225.
Zeevalk, G.D. and Nicklas, W.J. (1992) Evidence that the loss of the voltage-dependent Mg2+ block at the N-methyl-D- aspartate receptor underlies receptor activation during inhibition of neuronal metabolism. J. Neurochem., 59(4): 1211–1220.
Zhang, L., Rzigalinski, B.A., Ellis, E.F. and Satin, L.S. (1996) Reduction of voltage-dependent Mg2+ blockade of NMDA current in mechanically injured neurons. Science, 274(5294): 1921–1923.
Zurakowski, D., Vorwerk, C.K., Gorla, M., Kanellopoulos, A.J., Chaturvedi, N., Grosskreutz, C.L., Lipton, S.A. and Dreyer, E.B. (1998) Nitrate therapy may retard glaucomatous optic neuropathy, perhaps through modulation of glutamate receptors. Vision Res., 38(10): 1489–1494.